CRISPR/Cas9 technology generated a GAT to AAC change resulting in a aspartic acid to asparagine substitution at amino acid 564 (D564N) in exon 12. The human equivalent D565N mutation has been identified in spinal muscular atrophy with respiratory distress type I (SMARD1 patients.